Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration

Outlook Therapeutics, Inc. (Nasdaq: OTLK) has filed an application with the Centers for Medicare & Medicaid Services (CMS) for a permanent Healthcare Common Procedure Coding System (HCPCS) Level II J-code for its product LYTENAVA, aimed at treating wet age-related macular degeneration. This submission is part of the company's strategy to enhance U.S. commercialization and market access for LYTENAVA, which is the only FDA-approved ophthalmic bevacizumab for this condition. Outlook Therapeutics is targeting a commercial launch of LYTENAVA before the end of 2026.